TAF/EVG/Doxycycline Topical Insert
For more information, contact: Meredith Clark at clarkmr@odu.edu / conradinnovations@odu.edu
Development Stage:
Clinical – Phase 1 Trial (C1), IND-Enabling
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Topical - Fast Dissolving Insert – Vaginal, Rectal
Mechanism of Action:
Nucleoside analogue reverse transcriptase inhibitor (NRTI); Integrase strand-transfer inhibitor
Developer:
- CONRAD
Funding:
- Unspecified
Active Ingredient(s):
- Elvitegravir
- Tenofovir Alafenamide (TAF)
- Doxycycline
Product Indication(s):
- Chlamydia
- HIV
- HSV-2
- Bacterial STI's